{"transactions":[{"id":4637271,"issuer":{"id":2419,"kind":"organization","name":"4D Molecular Therapeutics, Inc.","symbol":"FDMT"},"owners":[{"id":20739,"kind":"person","name":"Kirn David","position":1,"cik":"0001834021","reported_name":"Kirn David","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Common Stock","published_at":"2026-10-07T21:11:47.000Z","date":"2026-10-05","kind":"sale","planned":true,"acquired":false,"shares":272,"price":13.6104,"value":3702.0288,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on January 9, 2026."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The transaction was executed in multiple trades in prices ranging from $13.61 to $13.63, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The reporting person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote."}],"balance_after":709153,"source":{"system":"sec-edgar","filing":"0001193125-26-417068","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1834021/000119312526417068/ownership.xml","form_type":"4"}},{"id":4637270,"issuer":{"id":2419,"kind":"organization","name":"4D Molecular Therapeutics, Inc.","symbol":"FDMT"},"owners":[{"id":20739,"kind":"person","name":"Kirn David","position":1,"cik":"0001834021","reported_name":"Kirn David","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Common Stock","published_at":"2026-10-07T21:11:47.000Z","date":"2026-10-05","kind":"sale","planned":true,"acquired":false,"shares":58061,"price":12.9215,"value":750235.2115,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on January 9, 2026."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The transaction was executed in multiple trades in prices ranging from $12.61 to $13.60, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The reporting person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote."}],"balance_after":709425,"source":{"system":"sec-edgar","filing":"0001193125-26-417068","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1834021/000119312526417068/ownership.xml","form_type":"4"}},{"id":4619813,"issuer":{"id":2419,"kind":"organization","name":"4D Molecular Therapeutics, Inc.","symbol":"FDMT"},"owners":[{"id":20739,"kind":"person","name":"Kirn David","position":1,"cik":"0001834021","reported_name":"Kirn David","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Common Stock","published_at":"2026-09-16T21:13:54.000Z","date":"2026-09-14","kind":"sale","planned":true,"acquired":false,"shares":58333,"price":13.903,"value":811003.699,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on January 9, 2026."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The transaction was executed in multiple trades in prices ranging from $13.43 to $14.15, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The reporting person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote."}],"balance_after":767486,"source":{"system":"sec-edgar","filing":"0001193125-26-393243","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1834021/000119312526393243/ownership.xml","form_type":"4"}},{"id":678476,"issuer":{"id":2419,"kind":"organization","name":"4D Molecular Therapeutics, Inc.","symbol":"FDMT"},"owners":[{"id":20739,"kind":"person","name":"Kirn David","position":1,"cik":"0001834021","reported_name":"Kirn David","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-08-21T20:06:38.000Z","date":"2026-08-19","kind":"exercise","planned":true,"acquired":false,"shares":50000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on January 9, 2026."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The shares underlying the stock option award shall vest and become exercisable as to 1/48th of the underlying shares on each monthly anniversary of March 6, 2025 (the \"Vesting Commencement Date\"), such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date, while the grantee remains a service provider to the Company."}],"balance_after":217500,"derivative":{"exercise_price":4.14,"expiration_date":"2035-03-05","underlying":"Common Stock","underlying_shares":50000},"source":{"system":"sec-edgar","filing":"0001193125-26-361096","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1650648/000119312526361096/ownership.xml","form_type":"4"}},{"id":678475,"issuer":{"id":2419,"kind":"organization","name":"4D Molecular Therapeutics, Inc.","symbol":"FDMT"},"owners":[{"id":20739,"kind":"person","name":"Kirn David","position":1,"cik":"0001834021","reported_name":"Kirn David","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Common Stock","published_at":"2026-08-21T20:06:38.000Z","date":"2026-08-19","kind":"sale","planned":true,"acquired":false,"shares":25927,"price":16.4173,"value":425651.3371,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on January 9, 2026."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The transaction was executed in multiple trades in prices ranging from $15.97 to $16.65, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The reporting person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote."}],"balance_after":825819,"source":{"system":"sec-edgar","filing":"0001193125-26-361096","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1650648/000119312526361096/ownership.xml","form_type":"4"}},{"id":678474,"issuer":{"id":2419,"kind":"organization","name":"4D Molecular Therapeutics, Inc.","symbol":"FDMT"},"owners":[{"id":20739,"kind":"person","name":"Kirn David","position":1,"cik":"0001834021","reported_name":"Kirn David","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Common Stock","published_at":"2026-08-21T20:06:38.000Z","date":"2026-08-19","kind":"sale","planned":true,"acquired":false,"shares":43149,"price":15.3566,"value":662621.9334,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on January 9, 2026."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The transaction was executed in multiple trades in prices ranging from $14.91 to $15.84, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The reporting person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote."}],"balance_after":851746,"source":{"system":"sec-edgar","filing":"0001193125-26-361096","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1650648/000119312526361096/ownership.xml","form_type":"4"}},{"id":678473,"issuer":{"id":2419,"kind":"organization","name":"4D Molecular Therapeutics, Inc.","symbol":"FDMT"},"owners":[{"id":20739,"kind":"person","name":"Kirn David","position":1,"cik":"0001834021","reported_name":"Kirn David","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Common Stock","published_at":"2026-08-21T20:06:38.000Z","date":"2026-08-19","kind":"exercise","planned":true,"acquired":true,"shares":50000,"price":4.14,"value":207000.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on January 9, 2026."}],"balance_after":894895,"source":{"system":"sec-edgar","filing":"0001193125-26-361096","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1650648/000119312526361096/ownership.xml","form_type":"4"}},{"id":695260,"issuer":{"id":2419,"kind":"organization","name":"4D Molecular Therapeutics, Inc.","symbol":"FDMT"},"owners":[{"id":20739,"kind":"person","name":"Kirn David","position":1,"cik":"0001834021","reported_name":"Kirn David","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Common Stock","published_at":"2026-08-05T20:10:51.000Z","date":"2026-08-04","kind":"sale","planned":true,"acquired":false,"shares":26842,"price":10.2301,"value":274596.3442,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on January 9, 2026."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The transaction was executed in multiple trades in prices ranging from $10.07 to $10.42, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The reporting person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote."}],"balance_after":844895,"source":{"system":"sec-edgar","filing":"0001193125-26-335115","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1650648/000119312526335115/ownership.xml","form_type":"4"}},{"id":696790,"issuer":{"id":2419,"kind":"organization","name":"4D Molecular Therapeutics, Inc.","symbol":"FDMT"},"owners":[{"id":20739,"kind":"person","name":"Kirn David","position":1,"cik":"0001834021","reported_name":"Kirn David","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Common Stock","published_at":"2026-08-04T20:45:29.000Z","date":"2026-08-03","kind":"sale","planned":true,"acquired":false,"shares":12415,"price":10.0461,"value":124722.3315,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on January 9, 2026."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The transaction was executed in multiple trades in prices ranging from $10.00 to $10.1250, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The reporting person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote."}],"balance_after":871737,"source":{"system":"sec-edgar","filing":"0001193125-26-333014","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1650648/000119312526333014/ownership.xml","form_type":"4"}},{"id":709524,"issuer":{"id":2419,"kind":"organization","name":"4D Molecular Therapeutics, Inc.","symbol":"FDMT"},"owners":[{"id":20739,"kind":"person","name":"Kirn David","position":1,"cik":"0001834021","reported_name":"Kirn David","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Common Stock","published_at":"2026-07-14T21:04:58.000Z","date":"2026-07-10","kind":"sale","planned":true,"acquired":false,"shares":442,"price":12.8355,"value":5673.291,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on January 9, 2026."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The transaction was executed in multiple trades in prices ranging from $12.82 to $12.88, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The reporting person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote."}],"balance_after":884152,"source":{"system":"sec-edgar","filing":"0001834021-26-000004","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1650648/000183402126000004/ownership.xml","form_type":"4"}},{"id":709523,"issuer":{"id":2419,"kind":"organization","name":"4D Molecular Therapeutics, Inc.","symbol":"FDMT"},"owners":[{"id":20739,"kind":"person","name":"Kirn David","position":1,"cik":"0001834021","reported_name":"Kirn David","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Common Stock","published_at":"2026-07-14T21:04:58.000Z","date":"2026-07-10","kind":"sale","planned":true,"acquired":false,"shares":15283,"price":12.0107,"value":183559.5281,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on January 9, 2026."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The transaction was executed in multiple trades in prices ranging from $11.575 to $12.49, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The reporting person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote."}],"balance_after":884594,"source":{"system":"sec-edgar","filing":"0001834021-26-000004","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1650648/000183402126000004/ownership.xml","form_type":"4"}},{"id":709522,"issuer":{"id":2419,"kind":"organization","name":"4D Molecular Therapeutics, Inc.","symbol":"FDMT"},"owners":[{"id":20739,"kind":"person","name":"Kirn David","position":1,"cik":"0001834021","reported_name":"Kirn David","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Common Stock","published_at":"2026-07-14T21:04:58.000Z","date":"2026-07-09","kind":"sale","planned":true,"acquired":false,"shares":42608,"price":12.8656,"value":548177.4848,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on January 9, 2026."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The transaction was executed in multiple trades in prices ranging from $12.68 to $13.23, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The reporting person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote."}],"balance_after":899877,"source":{"system":"sec-edgar","filing":"0001834021-26-000004","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1650648/000183402126000004/ownership.xml","form_type":"4"}},{"id":728577,"issuer":{"id":2419,"kind":"organization","name":"4D Molecular Therapeutics, Inc.","symbol":"FDMT"},"owners":[{"id":20739,"kind":"person","name":"Kirn David","position":1,"cik":"0001834021","reported_name":"Kirn David","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Common Stock","published_at":"2026-06-23T20:19:06.000Z","date":"2026-06-22","kind":"sale","planned":true,"acquired":false,"shares":114746,"price":10.4653,"value":1200851.3138,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on January 9, 2026."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The transaction was executed in multiple trades in prices ranging from $10.00 to $10.87, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The reporting person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote."}],"balance_after":942485,"source":{"system":"sec-edgar","filing":"0001834021-26-000002","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1650648/000183402126000002/ownership.xml","form_type":"4"}},{"id":754024,"issuer":{"id":2419,"kind":"organization","name":"4D Molecular Therapeutics, Inc.","symbol":"FDMT"},"owners":[{"id":20739,"kind":"person","name":"Kirn David","position":1,"cik":"0001834021","reported_name":"Kirn David","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Common Stock","published_at":"2026-06-02T20:48:55.000Z","date":"2026-06-01","kind":"sale","planned":true,"acquired":false,"shares":1922,"price":10.0197,"value":19257.8634,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on January 9, 2026."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The transaction was executed in multiple trades in prices ranging from $10.00 to $10.055, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The reporting person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote."}],"balance_after":1057231,"source":{"system":"sec-edgar","filing":"0001193125-26-253740","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1650648/000119312526253740/ownership.xml","form_type":"4"}},{"id":826073,"issuer":{"id":2419,"kind":"organization","name":"4D Molecular Therapeutics, Inc.","symbol":"FDMT"},"owners":[{"id":20739,"kind":"person","name":"Kirn David","position":1,"cik":"0001834021","reported_name":"Kirn David","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-03-27T20:30:07.000Z","date":"2026-03-25","kind":"grant","planned":false,"acquired":true,"shares":750000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares underlying the stock option award shall vest and become exercisable as to 1/48th of the underlying shares on each monthly anniversary of March 25, 2026 (the \"Vesting Commencement Date\"), such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date, while the grantee remains a service provider to the Company."}],"balance_after":750000,"derivative":{"exercise_price":9.88,"expiration_date":"2036-03-24","underlying":"Common Stock","underlying_shares":750000},"source":{"system":"sec-edgar","filing":"0001193125-26-129156","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1650648/000119312526129156/ownership.xml","form_type":"4"}},{"id":1214431,"issuer":{"id":2419,"kind":"organization","name":"4D Molecular Therapeutics, Inc.","symbol":"FDMT"},"owners":[{"id":20739,"kind":"person","name":"Kirn David","position":1,"cik":"0001834021","reported_name":"Kirn David","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2025-03-10T23:58:59.000Z","date":"2025-03-06","kind":"grant","planned":false,"acquired":true,"shares":267500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares underlying the stock option award shall vest and become exercisable as to 1/48th of the underlying shares on each monthly anniversary of March 6, 2025 (the \"Vesting Commencement Date\"), such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date, while the grantee remains a service provider to the Company."}],"balance_after":267500,"derivative":{"exercise_price":4.14,"expiration_date":"2035-03-05","underlying":"Common Stock","underlying_shares":267500},"source":{"system":"sec-edgar","filing":"0000950170-25-036688","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1650648/000095017025036688/ownership.xml","form_type":"4"}},{"id":1455142,"issuer":{"id":2419,"kind":"organization","name":"4D Molecular Therapeutics, Inc.","symbol":"FDMT"},"owners":[{"id":20739,"kind":"person","name":"Kirn David","position":1,"cik":"0001834021","reported_name":"Kirn David","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Stock Option (Right To Buy)","published_at":"2024-07-12T21:46:04.000Z","date":"2024-07-10","kind":"exercise","planned":true,"acquired":false,"shares":1270,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on March 21, 2024."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The shares underlying the stock option award shall vest and become exercisable as to 1/48th of the underlying shares on each monthly anniversary of February 1, 2022 (the \"Vesting Commencement Date\") while the grantee remains a service provider to the Company."}],"balance_after":148730,"derivative":{"exercise_price":15.78,"expiration_date":"2032-01-31","underlying":"Common Stock","underlying_shares":1270},"source":{"system":"sec-edgar","filing":"0000950170-24-083303","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1650648/000095017024083303/ownership.xml","form_type":"4"}},{"id":1455141,"issuer":{"id":2419,"kind":"organization","name":"4D Molecular Therapeutics, Inc.","symbol":"FDMT"},"owners":[{"id":20739,"kind":"person","name":"Kirn David","position":1,"cik":"0001834021","reported_name":"Kirn David","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Stock Option (Right To Buy)","published_at":"2024-07-12T21:46:04.000Z","date":"2024-07-10","kind":"exercise","planned":true,"acquired":false,"shares":11653,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on March 21, 2024."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The shares underlying the stock option award shall vest and become exercisable as to 1/48th of the underlying shares on each monthly anniversary of December 11, 2023 (the \"Vesting Commencement Date\"), such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date, while the grantee remains a service provider to the Company."}],"balance_after":565417,"derivative":{"exercise_price":14.42,"expiration_date":"2033-12-10","underlying":"Common Stock","underlying_shares":11653},"source":{"system":"sec-edgar","filing":"0000950170-24-083303","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1650648/000095017024083303/ownership.xml","form_type":"4"}},{"id":1455140,"issuer":{"id":2419,"kind":"organization","name":"4D Molecular Therapeutics, Inc.","symbol":"FDMT"},"owners":[{"id":20739,"kind":"person","name":"Kirn David","position":1,"cik":"0001834021","reported_name":"Kirn David","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2024-07-12T21:46:04.000Z","date":"2024-07-10","kind":"sale","planned":true,"acquired":false,"shares":12923,"price":22.4869,"value":290598.2087,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on March 21, 2024."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The transaction was executed in multiple trades in prices ranging from $22.05 to $23.00, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The reporting person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote."}],"balance_after":1059153,"source":{"system":"sec-edgar","filing":"0000950170-24-083303","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1650648/000095017024083303/ownership.xml","form_type":"4"}},{"id":1455139,"issuer":{"id":2419,"kind":"organization","name":"4D Molecular Therapeutics, Inc.","symbol":"FDMT"},"owners":[{"id":20739,"kind":"person","name":"Kirn David","position":1,"cik":"0001834021","reported_name":"Kirn David","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2024-07-12T21:46:04.000Z","date":"2024-07-10","kind":"exercise","planned":true,"acquired":true,"shares":1270,"price":15.78,"value":20040.6,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on March 21, 2024."}],"balance_after":1072076,"source":{"system":"sec-edgar","filing":"0000950170-24-083303","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1650648/000095017024083303/ownership.xml","form_type":"4"}},{"id":1455138,"issuer":{"id":2419,"kind":"organization","name":"4D Molecular Therapeutics, Inc.","symbol":"FDMT"},"owners":[{"id":20739,"kind":"person","name":"Kirn David","position":1,"cik":"0001834021","reported_name":"Kirn David","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2024-07-12T21:46:04.000Z","date":"2024-07-10","kind":"exercise","planned":true,"acquired":true,"shares":11653,"price":14.42,"value":168036.26,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on March 21, 2024."}],"balance_after":1070806,"source":{"system":"sec-edgar","filing":"0000950170-24-083303","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1650648/000095017024083303/ownership.xml","form_type":"4"}},{"id":1468588,"issuer":{"id":2419,"kind":"organization","name":"4D Molecular Therapeutics, Inc.","symbol":"FDMT"},"owners":[{"id":20739,"kind":"person","name":"Kirn David","position":1,"cik":"0001834021","reported_name":"Kirn David","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Stock Option (Right To Buy)","published_at":"2024-06-26T21:07:20.000Z","date":"2024-06-24","kind":"exercise","planned":true,"acquired":false,"shares":12930,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on March 21, 2024."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The shares underlying the stock option award shall vest and become exercisable as to 1/48th of the underlying shares on each monthly anniversary of December 11, 2023 (the \"Vesting Commencement Date\"), such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date, while the grantee remains a service provider to the Company."}],"balance_after":577070,"derivative":{"exercise_price":14.42,"expiration_date":"2033-12-10","underlying":"Common Stock","underlying_shares":12930},"source":{"system":"sec-edgar","filing":"0000950170-24-077944","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1650648/000095017024077944/ownership.xml","form_type":"4"}},{"id":1468587,"issuer":{"id":2419,"kind":"organization","name":"4D Molecular Therapeutics, Inc.","symbol":"FDMT"},"owners":[{"id":20739,"kind":"person","name":"Kirn David","position":1,"cik":"0001834021","reported_name":"Kirn David","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2024-06-26T21:07:20.000Z","date":"2024-06-24","kind":"sale","planned":true,"acquired":false,"shares":12930,"price":23.1022,"value":298711.446,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on March 21, 2024."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The transaction was executed in multiple trades in prices ranging from $22.69  to $23.36, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The reporting person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote."}],"balance_after":1059153,"source":{"system":"sec-edgar","filing":"0000950170-24-077944","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1650648/000095017024077944/ownership.xml","form_type":"4"}},{"id":1468586,"issuer":{"id":2419,"kind":"organization","name":"4D Molecular Therapeutics, Inc.","symbol":"FDMT"},"owners":[{"id":20739,"kind":"person","name":"Kirn David","position":1,"cik":"0001834021","reported_name":"Kirn David","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2024-06-26T21:07:20.000Z","date":"2024-06-24","kind":"exercise","planned":true,"acquired":true,"shares":12930,"price":14.42,"value":186450.6,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on March 21, 2024."}],"balance_after":1072083,"source":{"system":"sec-edgar","filing":"0000950170-24-077944","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1650648/000095017024077944/ownership.xml","form_type":"4"}},{"id":1648693,"issuer":{"id":2419,"kind":"organization","name":"4D Molecular Therapeutics, Inc.","symbol":"FDMT"},"owners":[{"id":20739,"kind":"person","name":"Kirn David","position":1,"cik":"0001834021","reported_name":"Kirn David","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2024-02-13T01:22:03.000Z","date":"2024-02-08","kind":"sale","planned":true,"acquired":false,"shares":92001,"price":27.1282,"value":2495821.5282,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on August 17, 2023."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The transaction was executed in multiple trades in prices ranging from $26.75 to $27.55, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The reporting person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote."}],"balance_after":1059153,"source":{"system":"sec-edgar","filing":"0000950170-24-014091","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1650648/000095017024014091/ownership.xml","form_type":"4"}},{"id":1670658,"issuer":{"id":2419,"kind":"organization","name":"4D Molecular Therapeutics, Inc.","symbol":"FDMT"},"owners":[{"id":20739,"kind":"person","name":"Kirn David","position":1,"cik":"0001834021","reported_name":"Kirn David","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2024-01-25T21:59:09.000Z","date":"2024-01-23","kind":"sale","planned":false,"acquired":false,"shares":5696,"price":18.4079,"value":104851.3984,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on August 17, 2023."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The transaction was executed in multiple trades in prices ranging from $18.06  to $18.76, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The reporting person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote."}],"balance_after":1151154,"source":{"system":"sec-edgar","filing":"0000950170-24-007477","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1650648/000095017024007477/ownership.xml","form_type":"4"}},{"id":1683634,"issuer":{"id":2419,"kind":"organization","name":"4D Molecular Therapeutics, Inc.","symbol":"FDMT"},"owners":[{"id":20739,"kind":"person","name":"Kirn David","position":1,"cik":"0001834021","reported_name":"Kirn David","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2024-01-08T21:19:01.000Z","date":"2024-01-05","kind":"sale","planned":true,"acquired":false,"shares":133,"price":20.105,"value":2673.965,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on August 17, 2023."},{"field":"price","element":"transactionPricePerShare","label":"F6","text":"The transaction was executed in multiple trades in prices ranging from $20.09 to $20.11, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The reporting person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote."}],"balance_after":1156850,"source":{"system":"sec-edgar","filing":"0000950170-24-002945","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1650648/000095017024002945/ownership.xml","form_type":"4"}},{"id":1683633,"issuer":{"id":2419,"kind":"organization","name":"4D Molecular Therapeutics, Inc.","symbol":"FDMT"},"owners":[{"id":20739,"kind":"person","name":"Kirn David","position":1,"cik":"0001834021","reported_name":"Kirn David","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2024-01-08T21:19:01.000Z","date":"2024-01-05","kind":"sale","planned":true,"acquired":false,"shares":28104,"price":19.5632,"value":549804.1728,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on August 17, 2023."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"The transaction was executed in multiple trades in prices ranging from $19.085 to $20.08, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The reporting person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote."}],"balance_after":1156983,"source":{"system":"sec-edgar","filing":"0000950170-24-002945","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1650648/000095017024002945/ownership.xml","form_type":"4"}},{"id":1683632,"issuer":{"id":2419,"kind":"organization","name":"4D Molecular Therapeutics, Inc.","symbol":"FDMT"},"owners":[{"id":20739,"kind":"person","name":"Kirn David","position":1,"cik":"0001834021","reported_name":"Kirn David","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2024-01-08T21:19:01.000Z","date":"2024-01-04","kind":"sale","planned":true,"acquired":false,"shares":40732,"price":20.3084,"value":827201.7488,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on August 17, 2023."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The transaction was executed in multiple trades in prices ranging from $20.02 to $20.545, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The reporting person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote."}],"balance_after":1185087,"source":{"system":"sec-edgar","filing":"0000950170-24-002945","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1650648/000095017024002945/ownership.xml","form_type":"4"}},{"id":1683631,"issuer":{"id":2419,"kind":"organization","name":"4D Molecular Therapeutics, Inc.","symbol":"FDMT"},"owners":[{"id":20739,"kind":"person","name":"Kirn David","position":1,"cik":"0001834021","reported_name":"Kirn David","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2024-01-08T21:19:01.000Z","date":"2023-12-18","kind":"sale","planned":true,"acquired":false,"shares":4702,"price":18.129,"value":85242.558,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on August 17, 2023."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The transaction was executed in multiple trades in prices ranging from $17.77 to $18.525, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The reporting person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote."}],"balance_after":1225819,"source":{"system":"sec-edgar","filing":"0000950170-24-002945","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1650648/000095017024002945/ownership.xml","form_type":"4"}},{"id":1683630,"issuer":{"id":2419,"kind":"organization","name":"4D Molecular Therapeutics, Inc.","symbol":"FDMT"},"owners":[{"id":20739,"kind":"person","name":"Kirn David","position":1,"cik":"0001834021","reported_name":"Kirn David","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2024-01-08T21:19:01.000Z","date":"2023-12-15","kind":"sale","planned":true,"acquired":false,"shares":28632,"price":17.2685,"value":494431.692,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on August 17, 2023."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The transaction was executed in multiple trades in prices ranging from $17.00 to $17.71, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The reporting person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote."}],"balance_after":1230521,"source":{"system":"sec-edgar","filing":"0000950170-24-002945","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1650648/000095017024002945/ownership.xml","form_type":"4"}},{"id":1712047,"issuer":{"id":2419,"kind":"organization","name":"4D Molecular Therapeutics, Inc.","symbol":"FDMT"},"owners":[{"id":20739,"kind":"person","name":"Kirn David","position":1,"cik":"0001834021","reported_name":"Kirn David","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2023-12-13T21:05:15.000Z","date":"2023-12-11","kind":"grant","planned":false,"acquired":true,"shares":590000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares underlying the stock option award shall vest and become exercisable as to 1/48th of the underlying shares on each monthly anniversary of December 11, 2023 (the \"Vesting Commencement Date\"), such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date, while the grantee remains a service provider to the Company."}],"balance_after":590000,"derivative":{"exercise_price":14.42,"expiration_date":"2033-12-10","underlying":"Common Stock","underlying_shares":590000},"source":{"system":"sec-edgar","filing":"0000950170-23-070013","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1650648/000095017023070013/ownership.xml","form_type":"4"}},{"id":1904008,"issuer":{"id":2419,"kind":"organization","name":"4D Molecular Therapeutics, Inc.","symbol":"FDMT"},"owners":[{"id":20739,"kind":"person","name":"Kirn David","position":1,"cik":"0001834021","reported_name":"Kirn David","relationship":{"director":true,"officer":true,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2023-05-05T00:09:22.000Z","date":"2023-05-02","kind":"gift","planned":false,"acquired":true,"shares":600000,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"Family Trusts"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Reflects gifts of shares by the Reporting Person to irrevocable trusts established for the benefit of the Reporting Person's children. The Goldman Sachs Trust Company of Delaware is the Trustee of such trusts."}],"balance_after":600000,"source":{"system":"sec-edgar","filing":"0001140361-23-023022","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1650648/000114036123023022/form4.xml","form_type":"4"}},{"id":1904007,"issuer":{"id":2419,"kind":"organization","name":"4D Molecular Therapeutics, Inc.","symbol":"FDMT"},"owners":[{"id":20739,"kind":"person","name":"Kirn David","position":1,"cik":"0001834021","reported_name":"Kirn David","relationship":{"director":true,"officer":true,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2023-05-05T00:09:22.000Z","date":"2023-05-02","kind":"gift","planned":false,"acquired":false,"shares":600000,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":1259153,"source":{"system":"sec-edgar","filing":"0001140361-23-023022","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1650648/000114036123023022/form4.xml","form_type":"4"}},{"id":1995229,"issuer":{"id":2419,"kind":"organization","name":"4D Molecular Therapeutics, Inc.","symbol":"FDMT"},"owners":[{"id":20739,"kind":"person","name":"Kirn David","position":1,"cik":"0001834021","reported_name":"Kirn David","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2023-02-24T00:56:02.000Z","date":"2023-02-22","kind":"sale","acquired":false,"shares":16449,"price":20.224,"value":332664.576,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The transaction was executed in multiple trades in prices ranging from $19.96 to $20.71, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The reporting person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote."}],"balance_after":1859153,"source":{"system":"sec-edgar","filing":"0001567619-23-003706","document":"doc1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1650648/000156761923003706/doc1.xml","form_type":"4"}},{"id":1995228,"issuer":{"id":2419,"kind":"organization","name":"4D Molecular Therapeutics, Inc.","symbol":"FDMT"},"owners":[{"id":20739,"kind":"person","name":"Kirn David","position":1,"cik":"0001834021","reported_name":"Kirn David","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2023-02-24T00:56:02.000Z","date":"2023-02-21","kind":"sale","acquired":false,"shares":907,"price":21.4897,"value":19491.1579,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The transaction was executed in multiple trades in prices ranging from $21.40 to $21.60, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The reporting person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote."}],"balance_after":1875602,"source":{"system":"sec-edgar","filing":"0001567619-23-003706","document":"doc1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1650648/000156761923003706/doc1.xml","form_type":"4"}},{"id":1995227,"issuer":{"id":2419,"kind":"organization","name":"4D Molecular Therapeutics, Inc.","symbol":"FDMT"},"owners":[{"id":20739,"kind":"person","name":"Kirn David","position":1,"cik":"0001834021","reported_name":"Kirn David","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2023-02-24T00:56:02.000Z","date":"2023-02-21","kind":"sale","acquired":false,"shares":17090,"price":20.9314,"value":357717.626,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The transaction was executed in multiple trades in prices ranging from $20.35 to $21.305, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The reporting person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote."}],"balance_after":1876509,"source":{"system":"sec-edgar","filing":"0001567619-23-003706","document":"doc1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1650648/000156761923003706/doc1.xml","form_type":"4"}},{"id":2015036,"issuer":{"id":2419,"kind":"organization","name":"4D Molecular Therapeutics, Inc.","symbol":"FDMT"},"owners":[{"id":20739,"kind":"person","name":"Kirn David","position":1,"cik":"0001834021","reported_name":"Kirn David","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2023-02-15T01:24:38.000Z","date":"2023-02-10","kind":"grant","acquired":true,"shares":222000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares underlying the stock option award shall vest and become exercisable as to 1/48th of the underlying shares on each monthly anniversary of February 10, 2023 (the \"Vesting Commencement Date\"), such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date, while the grantee remains a service provider to the Company"}],"balance_after":222000,"derivative":{"exercise_price":20.24,"expiration_date":"2033-02-09","underlying":"Common Stock","underlying_shares":222000},"source":{"system":"sec-edgar","filing":"0001567619-23-003008","document":"doc1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1650648/000156761923003008/doc1.xml","form_type":"4"}},{"id":2048402,"issuer":{"id":2419,"kind":"organization","name":"4D Molecular Therapeutics, Inc.","symbol":"FDMT"},"owners":[{"id":20739,"kind":"person","name":"Kirn David","position":1,"cik":"0001834021","reported_name":"Kirn David","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2023-01-24T00:57:33.000Z","date":"2023-01-20","kind":"sale","acquired":false,"shares":8625,"price":20.1886,"value":174126.675,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The transaction was executed in multiple trades in prices ranging from $20.01 to  $20.41, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The reporting person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote."}],"balance_after":1893599,"source":{"system":"sec-edgar","filing":"0001567619-23-001163","document":"doc1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1650648/000156761923001163/doc1.xml","form_type":"4"}},{"id":2048401,"issuer":{"id":2419,"kind":"organization","name":"4D Molecular Therapeutics, Inc.","symbol":"FDMT"},"owners":[{"id":20739,"kind":"person","name":"Kirn David","position":1,"cik":"0001834021","reported_name":"Kirn David","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2023-01-24T00:57:33.000Z","date":"2023-01-19","kind":"sale","acquired":false,"shares":10899,"price":20.0337,"value":218347.2963,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The transaction was executed in multiple trades in prices ranging from  $19.83 to  $20.28, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The reporting person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote."}],"balance_after":1902224,"source":{"system":"sec-edgar","filing":"0001567619-23-001163","document":"doc1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1650648/000156761923001163/doc1.xml","form_type":"4"}},{"id":2081044,"issuer":{"id":2419,"kind":"organization","name":"4D Molecular Therapeutics, Inc.","symbol":"FDMT"},"owners":[{"id":20739,"kind":"person","name":"Kirn David","position":1,"cik":"0001834021","reported_name":"Kirn David","relationship":{"director":true,"officer":true,"ten_percent_owner":true,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2022-12-19T22:56:53.000Z","date":"2022-12-16","kind":"sale","acquired":false,"shares":26349,"price":23.3863,"value":616205.6187,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"The transaction was executed in multiple trades in prices ranging from $23.19 to $23.74, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The reporting person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote."}],"balance_after":1913123,"source":{"system":"sec-edgar","filing":"0001567619-22-021815","document":"doc1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1650648/000156761922021815/doc1.xml","form_type":"4"}},{"id":2081043,"issuer":{"id":2419,"kind":"organization","name":"4D Molecular Therapeutics, Inc.","symbol":"FDMT"},"owners":[{"id":20739,"kind":"person","name":"Kirn David","position":1,"cik":"0001834021","reported_name":"Kirn David","relationship":{"director":true,"officer":true,"ten_percent_owner":true,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2022-12-19T22:56:53.000Z","date":"2022-12-16","kind":"sale","acquired":false,"shares":27595,"price":22.6625,"value":625371.6875,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The transaction was executed in multiple trades in prices ranging from $22.18 to $23.18, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The reporting person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote."}],"balance_after":1939472,"source":{"system":"sec-edgar","filing":"0001567619-22-021815","document":"doc1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1650648/000156761922021815/doc1.xml","form_type":"4"}},{"id":2081042,"issuer":{"id":2419,"kind":"organization","name":"4D Molecular Therapeutics, Inc.","symbol":"FDMT"},"owners":[{"id":20739,"kind":"person","name":"Kirn David","position":1,"cik":"0001834021","reported_name":"Kirn David","relationship":{"director":true,"officer":true,"ten_percent_owner":true,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2022-12-19T22:56:53.000Z","date":"2022-12-15","kind":"sale","acquired":false,"shares":1500,"price":24.1327,"value":36199.05,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The transaction was executed in multiple trades in prices ranging from $24.07 to $24.20, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The reporting person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote."}],"balance_after":1967067,"source":{"system":"sec-edgar","filing":"0001567619-22-021815","document":"doc1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1650648/000156761922021815/doc1.xml","form_type":"4"}},{"id":2081041,"issuer":{"id":2419,"kind":"organization","name":"4D Molecular Therapeutics, Inc.","symbol":"FDMT"},"owners":[{"id":20739,"kind":"person","name":"Kirn David","position":1,"cik":"0001834021","reported_name":"Kirn David","relationship":{"director":true,"officer":true,"ten_percent_owner":true,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2022-12-19T22:56:53.000Z","date":"2022-12-15","kind":"sale","acquired":false,"shares":31433,"price":23.5602,"value":740567.7666,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The transaction was executed in multiple trades in prices ranging from  $23.04 to  $24.04, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The reporting person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote."}],"balance_after":1968567,"source":{"system":"sec-edgar","filing":"0001567619-22-021815","document":"doc1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1650648/000156761922021815/doc1.xml","form_type":"4"}},{"id":2412826,"issuer":{"id":2419,"kind":"organization","name":"4D Molecular Therapeutics, Inc.","symbol":"FDMT"},"owners":[{"id":20739,"kind":"person","name":"Kirn David","position":1,"cik":"0001834021","reported_name":"Kirn David","relationship":{"director":true,"officer":true,"ten_percent_owner":true,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2022-02-03T22:40:53.000Z","date":"2022-02-01","kind":"grant","acquired":true,"shares":150000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares underlying the stock option award shall vest and become exercisable as to 1/48th of the underlying shares on each monthly anniversary of February 1, 2022 (the \"Vesting Commencement Date\") while the grantee remains a service provider to the Company."}],"balance_after":150000,"derivative":{"exercise_price":15.78,"expiration_date":"2032-01-31","underlying":"Common Stock","underlying_shares":150000},"source":{"system":"sec-edgar","filing":"0001567619-22-002466","document":"doc1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1650648/000156761922002466/doc1.xml","form_type":"4"}},{"id":2796193,"issuer":{"id":2419,"kind":"organization","name":"4D Molecular Therapeutics, Inc.","symbol":"FDMT"},"owners":[{"id":20739,"kind":"person","name":"Kirn David","position":1,"cik":"0001834021","reported_name":"Kirn David","relationship":{"director":true,"officer":true,"ten_percent_owner":true,"other":false,"officer_title":"See Remarks"}}],"security":"Stock Option (Right to Buy)","published_at":"2021-03-10T21:05:44.000Z","date":"2021-03-08","kind":"grant","acquired":true,"shares":150000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares underlying the stock option award shall vest and become exercisable as to 1/48th of the underlying shares on each monthly anniversary of March 8, 2021 (the \"Vesting Commencement Date\") while the grantee remains a service provider to the Company."}],"balance_after":150000,"derivative":{"exercise_price":41.66,"expiration_date":"2031-03-07","underlying":"Common Stock","underlying_shares":150000},"source":{"system":"sec-edgar","filing":"0001567619-21-005967","document":"doc1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1650648/000156761921005967/doc1.xml","form_type":"4"}}]}